Who is sponsoring NCT05799859?

NCT05799859 is sponsored by Medical University of Graz.

What drugs are being tested in NCT05799859?

Interventions in NCT05799859: Use of coronally advanced flap (CAF) and collagen matrix (CM), Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD)..

What condition does NCT05799859 study?

NCT05799859 studies Gingival Recession.

Is NCT05799859 still recruiting?

NCT05799859 is currently completed. Last updated 5 April 2023.

Last reviewed 2023-04-05 · How we verify

NCT05799859: EmdoDerm

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Local Gingival Recession With an Enamel Matrix Protein Coated Collagen Matrix

Completed NA Last updated 5 April 2023

What this trial tests

NA trial testing Use of coronally advanced flap (CAF) and collagen matrix (CM) in Gingival Recession in 15 participants. Completed in 22 September 2022.

Timeline

9 January 2017

Primary endpoint
22 September 2022

22 September 2022

Quick facts

Lead sponsor	Medical University of Graz
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	15
Start date	9 January 2017
Primary completion	22 September 2022
Estimated completion	22 September 2022

Drugs / interventions tested

Use of coronally advanced flap (CAF) and collagen matrix (CM)
Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).

Conditions studied

Gingival Recession — all drugs for Gingival Recession →

Sponsor

Medical University of Graz

Who can join

Adults 19 to 79, any sex, with Gingival Recession. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The clinical trial studies patients with gingival recession defects (receding gums). The goal of the study is to test whether the additional use of enamel matrix derivatives (EMD), combined with the use of a coronally advance flap (CAF) and a CM (collagen matrix), shows a better outcome compared to a comparison group. The comparison group comprises patients receiving treatment with CAF and CM without the use of EMD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment of Localized Gingival Recession with an Enamel Matrix Protein-Coated Xenogeneic Dermal Matrix: A Randomized Controlled Trial.
Rieder M, Wimmer G, Sokolowski A, Sokolowski A, et al · · 2024 · cited 1× · PMID 39203163 · DOI 10.3390/ma17163985

Verify or expand the search:

Other recruiting trials for Gingival Recession

Currently open trials in the same condition.

NCT07513792 — The Impact of a 3D Imaging Tool on Reducing Gum Recession During Orthodontic Treatment With Aligners · NA · recruiting
NCT07437417 — A Novel Volume Stable Matrix for Gingival Recession Coverage at Teeth · NA · recruiting
NCT07158541 — Comparing TCAF and MTUN With Soft Tissue Grafting for Treating Single Recessions in the Premandible · NA · recruiting
NCT07104019 — Biofiller and Gingival Phenotype Thickening · NA · recruiting
NCT07291583 — Hyaluronic Acid With Connective Tissue Grafting for Gingival Recession · NA · active not recruiting

Other Medical University of Graz trials

Trials by the same sponsor.

NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05799859 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
Last refreshed: 5 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05799859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing